Citation: S. Spreat et J. Conroy, USE OF PSYCHOTROPIC MEDICATIONS FOR PERSONS WITH MENTAL-RETARDATION WHO LIVE IN OKLAHOMA NURSING-HOMES, Psychiatric services, 49(4), 1998, pp. 510-512
Citation: S. Spreat et al., IMPROVE QUALITY IN NURSING-HOMES OR INSTITUTE COMMUNITY PLACEMENT - IMPLEMENTATION OF OBRA FOR INDIVIDUALS WITH MENTAL-RETARDATION, Research in developmental disabilities, 19(6), 1998, pp. 507-518
Citation: D. Behar et al., EXTREME REDUCTION OF METHYLPHENIDATE LEVELS BY CARBAMAZEPINE, Journal of the American Academy of Child and Adolescent Psychiatry, 37(11), 1998, pp. 1128-1129
Citation: S. Spreat et al., USE OF PSYCHOTROPIC MEDICATION IN OKLAHOMA - A STATEWIDE SURVEY, American journal of mental retardation, 102(1), 1997, pp. 80-85
Citation: S. Spreat et L. Connelly, RELIABILITY-ANALYSIS OF THE MOTIVATION ASSESSMENT SCALE, American journal of mental retardation, 100(5), 1996, pp. 528-532
Citation: S. Spreat et De. Walsh, IMPACT OF TREATMENT EFFICACY AND PROFESSIONAL AFFILIATION ON RATINGS OF TREATMENT ACCEPTABILITY, MENTAL RETA, 32(3), 1994, pp. 227-233
Citation: S. Spreat et D. Behar, TRENDS IN THE RESIDENTIAL (INPATIENT) TREATMENT OF INDIVIDUALS WITH ADUAL DIAGNOSIS, Journal of consulting and clinical psychology, 62(1), 1994, pp. 43-48
Citation: S. Spreat et al., TRANQUILIZER REDUCTION TRIALS IN A RESIDENTIAL PROGRAM FOR PERSONS WITH MENTAL-RETARDATION, Hospital & community psychiatry, 44(11), 1993, pp. 1100-1102